Intervention

pharmacogenomic studies

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 14 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14
Recruiting0
Common conditions25
Lead sponsors shown12
Advertisement

Clinical trials

14 shown
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line ChemotherapyNCT01208064 · 2011-07-01
TERMINATED
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer SurvivorsNCT01196936 · 2010-09-01
ACTIVE_NOT_RECRUITING
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast CancerNCT00873366 · 2009-05-01
TERMINATED
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2NCT00967239 · 2009-04-01
UNKNOWN
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by SurgeryNCT00936832 · 2009-04-01
WITHDRAWN
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainNCT01316744 · 2009-04-01
UNKNOWN
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast CancerNCT00755885 · 2008-10-01
COMPLETED
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving TamoxifenNCT00764322 · 2008-06-18
COMPLETED
White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer SurvivorsNCT00709020 · 2008-06-01
COMPLETED
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT01557959 · 2007-07-01
COMPLETED
AZD2171 in Treating Patients With Recurrent Small Cell Lung CancerNCT00245063 · 2006-03-01
COMPLETED
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by SurgeryNCT00665457 · 2004-04-15
TERMINATED
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast CancerNCT00645866 · 2003-04-01
COMPLETED
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckNCT00063895 · 2003-04-01
COMPLETED

Common conditions

Breast Cancer8Recurrent Non-small Cell Lung Cancer3Stage IIIB Non-small Cell Lung Cancer2Stage IV Non-small Cell Lung Cancer2Adenocarcinoma of the Lung1Adenosquamous Cell Lung Cancer1Bronchoalveolar Cell Lung Cancer1Cancer1Cancer Survivor1Colorectal Cancer1Large Cell Lung Cancer1Lung Cancer1Menopausal Symptoms1Metastatic Cancer1Non-small Cell Lung Cancer1Recurrent Ovarian Epithelial Cancer1Recurrent Squamous Cell Carcinoma of the Hypopharynx1Recurrent Squamous Cell Carcinoma of the Larynx1Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity1Recurrent Squamous Cell Carcinoma of the Nasopharynx1Recurrent Squamous Cell Carcinoma of the Oropharynx1Squamous Cell Lung Cancer1Stage III Squamous Cell Carcinoma of the Hypopharynx1Stage III Squamous Cell Carcinoma of the Larynx1Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity1

Trial status mix

COMPLETED7
TERMINATED3
UNKNOWN2
ACTIVE_NOT_RECRUITING1
WITHDRAWN1

Phase mix

PHASE210
PHASE13
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.